Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib in monotherapy and combination with chemotherapy for acute myeloid leukemia
2016-003353-16Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of entospletinib in acute myeloid leukemia (AML) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Safety. Started Nov 2016; status: completed.
02
Drugs
entospletinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-003353-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003353-16.